
METHODS AND STANDARDS OF ESTABLISHING PAYMENT RATES - OTHER MEDICAL CARE
(Continued)

12. a. Prescribed Drugs (continued)

(4) Payment for Clotting Factors through Hemophilia Treatment Center specialty pharmacies will be reimbursed at the lowest of:

- a. The Wholesale Acquisition Cost (WAC) + 0% + PDF;
- b. The State Maximum Allowable Cost (SMAC) + PDF;
- c. AWP-19% + PDF;
- d. Submitted Ingredient Cost + Submitted dispensing fee;
- e. The provider's Usual and Customary (U&C) charges; or
- f. The Gross Amount Due (GAD).

(5) Facilities purchasing drugs through the Federal Supply Schedule (FSS) or the drug pricing program under 38 U.S.C. 1826, 42 U.S.C. 256b, or 42 U.S.C. 1396-8, other than the 340B drug pricing program will be reimbursed no more than the actual acquisition cost for the drug plus a \$11.13 professional dispensing fee.

(6) Facilities purchasing drugs at Nominal Price (outside of 340B or FSS), will be reimbursed no more than the Actual Acquisition Cost for the drug plus a \$11.13 Professional Dispensing Fee. Nominal Price as defined in 447.502 of the Code of Federal Regulations, Part 42 means a price that is less than 10% of the average manufacturer price (AMP) in the same quarter for which the AMP is computed.

(7) Investigational drugs are not a covered service under the DVHA pharmacy program.

(8) High-Investment Carve-Out Drugs must be billed separately from the inpatient DRG claim and cannot be acquired through the 340B program. These inpatient drugs will be paid at the actual acquisition cost, and providers must submit an invoice documenting costs. The High-Investment Carve-Out Drug List is available on the DVHA website.

GCR# 17-10422-0019

Effective Date: 01/01/181/1/2023

Supersedes

GCR# 17-000517-104 Last TN: 17-0005

Approval Date: N/A